Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease Mice

17 Feb 2021

Abstract excerpt

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease characterized by a late clinical onset of psychiatric, cognitive, and motor symptoms. Transcriptional dysregulation is an early and central disease mechanism which is accompanied by epigenetic alterations in HD. Previous studies demonstrated that targeting transcriptional changes by inhibition of histone deacetylases (HDACs), especially...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Neurodegenerative Diseases
Share to Parkinson's Disease Mechanisms and Treatments
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33679321
DOI: 10.3389/fnmol.2021.616886

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease MicePMID 33679321Read ↗

Selective inhibition of histone deacetylase 1 and 3 improves motor phenotype and alleviates transcriptional dysregulation in Huntington’s disease miceSemantic proximity Read ↗

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.Semantic proximity Read ↗

The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.Semantic proximity Read ↗

Evaluation of Histone Deacetylases as Drug Targets in Huntington’s Disease modelsStudy of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.Semantic proximity Read ↗

A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.Semantic proximity Read ↗

Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease miceSemantic proximity Read ↗

HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation.Semantic proximity Read ↗

LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's diseaseSemantic proximity Read ↗

Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.Semantic proximity Read ↗

Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s diseaseSemantic proximity Read ↗

SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.Semantic proximity Read ↗

Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular DystrophiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.